Last reviewed · How we verify
Minocycline IV
At a glance
| Generic name | Minocycline IV |
|---|---|
| Also known as | Minocin® |
| Sponsor | Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2) (PHASE3)
- Minocycline as Neuroprotectant After Aneurysmal Subarachnoid Hemorrhage (PHASE1, PHASE2)
- Safety and PK Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Minocin IV (PHASE1)
- A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting
- Pharmacokinetic Evaluation and Local Tolerability of Dry Powder Amikacin Via the Cyclops™ (PHASE1)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minocycline IV CI brief — competitive landscape report
- Minocycline IV updates RSS · CI watch RSS
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) portfolio CI